T. Seiwert
University of Chicago
13 Papers
34 Citations
T. Seiwert is an academic researcher from University of Chicago. The author has contributed to research in topics: Medicine & Head and neck squamous-cell carcinoma. The author has an hindex of 9, co-authored 13 publications.
Chat about Author
Papers
Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy
Yu Pei Chen,Y. Q. Wang,Jia Wei Lv,Y. Q. Li,Melvin L.K. Chua,Q.T. Le,Nancy Y. Lee,A. Dimitrios Colevas,T. Seiwert,David N. Hayes,Nadeem Riaz,Jan B. Vermorken,Brian O'Sullivan,Q. M. He,X. J. Yang,Ling-Long Tang,Yan Ping Mao,Ying Sun,Na Liu,Jun Ma +19 more
TL;DR: This study revealed a novel Immune Class in HNSC; two subclasses characterized by active or exhausted immune responses were also identified, providing new insights into tailoring immunotherapeutic strategies for different HN SC subgroups.
257
Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing
Christine H. Chung,Violeta Beleva Guthrie,David L. Masica,Collin Tokheim,Hyunseok Kang,Jeremy D. Richmon,Nishant Agrawal,Carole Fakhry,Harry Quon,Rathan M. Subramaniam,Zhixiang Zuo,T. Seiwert,Zachary R. Chalmers,G.M. Frampton,Siraj M. Ali,Roman Yelensky,Phillip J. Stephens,V.A. Miller,Rachel Karchin,Justin A. Bishop +19 more
TL;DR: The genomic profile of FFPE HNSCC tumors obtained through routine clinical practice is comparable with frozen tumors studied in research setting, demonstrating the feasibility of comprehensive genomic profiling in a clinical setting.
188
Molecular pathways in head and neck cancer: EGFR, PI3K, and more.
Amanda Psyrri,T. Seiwert,Antonio Jimeno +2 more
- 01 Jan 2013
TL;DR: The first molecular targeting strategy to demonstrate a survival advantage for patients with HNSCC has emerged in the context of EGFR biology and multiple therapeutic strategies targeting PI3K are being explored, and multiple agents either alone or in combination are in development.
82
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
Joseph K. Salama,Daniel J. Haraf,Kerstin M. Stenson,Elizabeth A. Blair,M. E. Witt,R. Williams,R. Kunnavakkam,Ezra E.W. Cohen,T. Seiwert,Everett E. Vokes +9 more
TL;DR: The addition of bevacuzimab to chemoradiotherapy for HNSCC should be limited clinical trials, and locoregional progression seen in T4N0-1 tumors treated with BFHX was unexpected and led to study termination.
60
Lba31a phase ib study of pembrolizumab (pembro; mk-3475) in patients (pts) with human papiilloma virus (hpv)-positive and negative head and neck cancer (hnc)
Laura Q.M. Chow,Barbara Burtness,Jared Weiss,Raanan Berger,Joseph Paul Eder,Edward Gonzalez,J. Pulini,J. Johnson,Marisa Dolled-Filhart,Kenneth Emancipator,Jared Lunceford,Kumudu Pathiraja,Christine K. Gause,Jonathan D. Cheng,T. Seiwert +14 more
TL;DR: Pembro is safe and tolerable and shows antitumor activity in both HPV+ and HPV-Advanced HNC and these findings support further development of pembro in advanced HNC.
31